Earnings
HLS Therapeutics Announces Q1 2026 Financial Results
HLS Therapeutics Debt Reduction and NILEMDO Launch Execution Validate Operational Turnaround Despite Modest Revenue Growth
Executive Summary
- HLS Therapeutics reported Q1 2026 financial results on May 15, 2026.
- Revenue increased 2% year-over-year to $12.9 million, driven by Vascepa sales growth of 15%.
- Net loss narrowed significantly to ($2.3) million from ($4.4) million in Q1 2025.
- Cash from operations surged 80% year-over-year to $6.4 million.
- Net debt reduced by 32% year-over-year to $31.9 million, with $5.1 million in principal repayments made during the quarter.
- NILEMDO™ launched commercially in April 2026; early weekly sales are running ahead of forecast.
- Private payers Canada Life and Sun Life added NILEMDO without prior authorization.
- Full-year 2026 guidance reaffirmed: Revenue $56–60 million, Adjusted EBITDA $18.5–21 million.
Material Impact
- The Q1 results confirm the operational improvements highlighted in the Fiscal 2025 earnings released March 12, 2026.
- Profitability improvement is notable (loss narrowed by ~47%), but revenue growth remains modest (+2%).
- Debt reduction trajectory continues from FY25 ($17.8M repaid) to Q1 2026 ($5.1M repaid), strengthening the balance sheet without dilution.
- NILEMDO launch execution is positive ("ahead of forecast"), but this was anticipated following the March announcement of the April launch date.
- Reaffirmation of guidance suggests management sees no immediate need to revise expectations upward despite better-than-expected cash flow and loss reduction.
- The news validates the strategy rather than introducing a new catalyst, making it incremental relative to previous market expectations set in March 2026.
HLS · Price
Company Overview
- Company: HLS Therapeutics Inc., a Canadian pharmaceutical company focused on cardiovascular and psychiatric medicines.
- Flagship Project 1 (Vascepa): Prescription omega-3 acid ethyl esters for cardiovascular health; driving the majority of revenue growth (+15% YoY).
- Flagship Project 2 (NILEMDO™): Bempedoic acid, a non-statin oral therapy for LDL-C reduction. Launched April 2026 in Canada following Health Canada approval Nov 2025.
- Flagship Project 3 (Clozaril): Antipsychotic medication; sales declining (-4% Q3 2025) but stabilizing in Ontario volumes as of March/April 2026.
- Pipeline: NEXLIZET® (bempedoic acid/ezetimibe combination) targeted for H1 2027 launch pending regulatory clearance.
More from HLS THERAPEUTICS INC. J
Mar 12, 2026 · 06:30